Previous 10 | Next 10 |
Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets Canada NewsWire VANCOUVER, June 27, 2019 - Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Exploring non-dilutive op...
- Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor - - Fast Track Designation assures frequent communication with FDA, often leading ...
- MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 – - World renowned myelofibrosis expert Dr. Srdan Verstovsek named Chief Investigator of the MOMENTUM Phase 3 study - - 180 patient 2:1 randomized, double blind clinical...
Gainers: Genocea Biosciences (NASDAQ: GNCA ) +45% . Mirati Therapeutics (NASDAQ: MRTX ) +34% . Cypress Semiconductor (NASDAQ: CY ) +25% . ARCA biopharma (NASDAQ: ABIO ) +23% . Centrus Energy (NYSEMKT: LEU ) +18% . Spirit MTA REIT (NYSE: SMTA ) +18% . El Paso Electric (NYSE: EE ...
Genocea Biosciences (NASDAQ: GNCA ) +94% on positive GEN-009 data in cancer patients. More news on: Genocea Biosciences, Inc., Cypress Semiconductor Corporation, Outlook Therapeutics, Inc., Stocks on the move, Read more ...
Sierra Oncology (NASDAQ: SRRA ) holds an analyst and investor event featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit, to discuss clinical findings and possible next steps for its oral, highly selective Chk1 inhibitor, SRA737. More news on: Sierra On...
Sierra Holds Analyst & Investor Event for SRA737 Sierra Holds Analyst & Investor Event for SRA737 Canada NewsWire VANCOUVER, June 3, 2019 - Sierra management and distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit discuss clinical findin...
Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration Canada NewsWire VANCOUVER, June 1, 2...
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York Canada NewsWire VANCOUVER, May 28, 2019 - Presentation scheduled for 8:00 am ET on June 5, 2019 - VANCOUVER , May 28, 2019 /CNW/ - Sierra Oncology, I...
Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO Canada NewsWire VANCOUVER, May 15, 2019 - SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1 st - - Sierra to hold Analys...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...